STAR Cape+BKM120 MBC with Brain Met - Adventist HealthCare

Skip to Content

Clinical Trial Details

STAR Cape+BKM120

STAR Cape+BKM120 MBC with Brain Met


Request Additional Trial Information
Full Trial Details:

Condition: Breast Cancer
Study Type: Interventional
Phase: Phase II
Study Start Date: 05/01/2014
Study Completion Date: 01/31/2018

This is a study to determine the safety and effectiveness of BKM120 plus capecitabine in breast cancer patients with brain metastases. Both capecitabine and BMK120 have previously shown acivity in patients with breast cancer. Like capecitabine, BMK120 is also effective in crossing the blood brain barrier making it a preferred candidate for its evaluation in patients with metastatic breast cancer(MBC).

NCT Number
Principal Investigator(s)
John Wallmark, MD
US Oncology Research
Participant Eligibility
  • Age: 18 - No Maximum
  • Gender: Female


  • Shady Grove Adventist Aquilino Cancer Center
    9905 Medical Center Drive
    Rockville, MD 20850
    Main: 240-826-6297

Clincal Trials & Research Studies

Patient Stories

We’re writing new chapters in the lives of our patients, their families and our community daily. These are their stories:

Local Health News - In Your Inbox

Join over 100k of your friends & neighbors and get the latest news about community health programs and events when you sign-up for Adventist HealthCare & You Digital.

Subscribe Today!